Nomura Asset Management Co. Ltd. Reduces Holdings in Illumina, Inc. (NASDAQ:ILMN)

Nomura Asset Management Co. Ltd. reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 12.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,398 shares of the life sciences company's stock after selling 6,195 shares during the period. Nomura Asset Management Co. Ltd.'s holdings in Illumina were worth $5,933,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in ILMN. WCM Investment Management LLC boosted its holdings in Illumina by 26.6% during the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock valued at $551,625,000 after acquiring an additional 867,673 shares during the period. Bank of New York Mellon Corp lifted its position in Illumina by 0.8% in the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock valued at $454,617,000 after purchasing an additional 27,618 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Illumina by 1.8% during the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company's stock valued at $354,933,000 after purchasing an additional 48,018 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock valued at $282,735,000 after purchasing an additional 625,245 shares during the period. Finally, Norges Bank bought a new position in shares of Illumina in the fourth quarter worth approximately $228,714,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Illumina Stock Performance

Shares of Illumina stock traded down $2.26 during trading on Friday, hitting $74.16. 3,912,056 shares of the company's stock traded hands, compared to its average volume of 2,222,582. Illumina, Inc. has a 1 year low of $70.64 and a 1 year high of $156.66. The business has a 50-day simple moving average of $96.82 and a 200-day simple moving average of $125.06. The stock has a market capitalization of $11.75 billion, a P/E ratio of -9.66, a PEG ratio of 1.60 and a beta of 1.38. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. HSBC cut shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target for the company. in a research report on Friday, February 28th. Morgan Stanley reduced their price target on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 11th. Piper Sandler lifted their price target on Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. TD Cowen lowered Illumina from a "buy" rating to a "hold" rating and lowered their price objective for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Finally, Barclays reaffirmed an "underweight" rating on shares of Illumina in a research report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Illumina currently has an average rating of "Moderate Buy" and a consensus price target of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.